Trial Profile

A Phase 1, Open-Label, Dose-Ranging Study of the PD-1 Probody Therapeutic CX-188 in Adults With Recurrent or Metastatic Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX-188 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms PROCLAIM-CX-188
Sponsors CytomX Therapeutics

Most Recent Events

30 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
26 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jan 2020.
15 Mar 2019 Planned initiation date changed from 1 Nov 2018 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com